Clinical findings and gingival crevicular fluid prostaglandin E2 and interleukin-1-beta levels following initial periodontal treatment and short-term meloxicam administration

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 11, 2010, Pages 1805-1812

  Buduneli, Nurcan ^a   Buduneli, Eralp ^a   Çetin, Emel Yk ^a   Kirilmaz, Levent ^a   Ktkçler, Necil ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

ELISA; Gingival crevicular fluid; Nonsteroidal anti inflammatory drugs; Periodontal treatment; Periodontitis

Indexed keywords

INTERLEUKIN 1BETA; MELOXICAM; PLACEBO; PROSTAGLANDIN E2; NONSTEROID ANTIINFLAMMATORY AGENT; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRIEDMAN TEST; GINGIVITIS; HUMAN; MALE; PERIODONTITIS; PREVENTIVE DENTISTRY; RANDOMIZED CONTROLLED TRIAL; TABLET; TREATMENT OUTCOME; CHRONIC DISEASE; METABOLISM; MIDDLE AGED;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; DINOPROSTONE; DOUBLE-BLIND METHOD; FEMALE; GINGIVAL CREVICULAR FLUID; HUMANS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; PERIODONTITIS; PLACEBOS; THIAZINES; THIAZOLES;

EID: 77954781213     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.490555     Document Type: Article

References (36)

1. Jeffcoat MK, Williams KC, Redely MS, et al. Flurbiprofen treatment of human periodontitis: effect on alveolar bone height ane metabolism. J Perioeontal Res 1988;23:381-385
2. Reddy MS, Palcanis KG, Barnett ML, et al. Efficacy of meclofenomate sodium (Meclomen) in the treatment of rapidly progressive periodontitis. J Clin Periodontol 1993;20:635-640
3. Xie W, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by RNA splicing. Proc Natl Acad Sci USA 1991;88:2692-2696
4. Vane JR. Towards a better aspirin. Nature 1994;367:215-216
5. Engelhardt G. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Br J Rheumatol 1996;35(Suppl 1):4-12
6. Bezerra MM, Lima V, Alencar VBM, et al. Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats. J Periodontol 2000;71:1009-1014
7. Pelletier JP, Pelletier JM. Effects of nimesulide and naproxen on the degradation and metalloprotease synthesis of human osteoartritic cartilage. Drugs 1993;46(Suppl 1):34-39
8. Buduneli N, Vardar S, Atilla G, et al. Gingival crevicular fluid matrix metalloproteinase-8 levels following adjunctive use of meloxicam and initial phase of periodontal therapy. J Periodontol 2002;73:103-109
9. Cetin EO, Buduneli N, Atlihan E, Kirilmaz L. In vitro studies of a degradable device for controlled-release of meloxicam. J Clin Periodontol 2005;32:773-777
10. Offenbacher S. Periodontal diseases: pathogenesis. Ann Periodontol 1996;1:879-925
11. Offenbacher S, Heasman PA, Collins JG. Modulation of host PGE2 secretion as a determinant of periodontal disease expression. J Periodontol 1993;64:432-444
12. Offenbacher S, Odle BM, Braswell LD, et al. Changes in cyclooxygenase metabolites in experimental periodontitis in Macaca mulatta. J Periodont Res 1989;24:63-74
13. Dinarello CA, Wolf SM. The role of interleukin-1 in disease. N Engl J Med 1993;14:106-113
14. Vardar S, Buduneli E, Baylas H, et al. Individual and combined effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on endotoxin-induced periodontitis in rats. J Periodontol 2005;76:99-106
15. Vardar-Sengul S, Buduneli N, Buduneli E, et al. Effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on serum interleukin-1beta, osteocalcin, and C-reactive protein levels in rats. J Periodontol 2006;77:657-663
16. Vardar-S engul S, Buduneli E, Turkoglu O, et al. The effects of selective COX-2 inhibitor/celecoxib and omega-3 fatty acid on matrix metalloproteinases, TIMP-1, and laminin-5gamma2 chain immunolocalization in experimental periodontitis. J Periodontol 2008;79:1934-1941
17. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999;4:1-6
18. Saxer UP, Muhleman HR Motivation and instruction [in German]. Sch MZZ 1975;85:905-919
19. Badersten A, Nilveus R, Egelberg J. Effect of non-surgical periodontal therapy. (IV) Operator variability. J Clin Periodontol 1985;12:723-729
20. Buduneli N, Kutukculer N, Aksu G, Atilla G. Evaluation of transforming growth factor-beta1 level in crevicular fluid of cyclosporine A-treated patients. J Periodontol 2001;72:526-531
21. Hotz G. Medical treatment of postoperative and posttraumatic swellings [in German]. ZWR 1986;95:256-261
22. Lamster IB, Hartley LJ, Oshrain RL. Evaluation and modification of spectrophotometric procedures for analysis of lactate dehydrogenase, beta-glucuronidase and arylsulphatase in human gingival crevicular fluid collected with filter-paper strips. Arch Oral Biol 1985;30:235-242
23. Lamster IB, Oshrain RL, Gordon JM. Enzyme activity in human gingival crevicular fluid: considerations in data reporting based on analysis of individual crevicular sites. J Clin Periodontol 1986;13:799-804
24. Offenbacher S, Farr DH, Goodson JM. Measurement of prostaglandin E in gingival crevicular fluid. J Clin Periodontol 1981;8:359-367
25. Offenbacher S, Odle BM, Gray RC, Van Dyke TE. Crevicular fluid prostaglandin E levels as a measure of the periodontal disease status of adult and juvenile periodontitis patients. J Periodont Res 1984;19:1-13
26. Soder B. Neutrophil elastase activity, levels of prostaglandin E2, and matrix metalloproteinase-8 in refractory periodontitis sites in smokers and non-smokers. Acta Odontol Scand 1999;57:77-82
27. Vane JR, Botting RM. Anti-inflammatory drugs and their mechanism of action. Inflamm Res 1998;47(Suppl 2):S78-87
28. Toker H, Marakoglu I, Poyraz O. Effect of meloxicam on gingival crevicular fluid IL-1beta and IL1 receptor antagonist levels in subjects with chronic periodontitis, and its effects on clinical parameters. Clin Oral Investig 2006;10:305-310
29. Azoubel MCF, Sarmento VA, Cangussu V, et al. Adjunctive benefits of systemic etoricoxib in non-surgical treatment of aggressive periodontitis: short-term evaluation. J Periodontol 2008;79:1719-1725
30. Yen CA, Damoulis PD, Stark PC, et al. The effect of a selective cyclooxygenase-2 inhibitor (Celecoxib) on chronic periodontitis. J Periodontol 2008;79:104-113
31. Oliveira TM, Sakai VT, Machado MA, et al. COX-2 inhibition decreases VEGF expression and alveolar bone loss during the progression of experimental periodontitis in rats. J Periodontol 2008;79:1062-1069
32. Greenwald RA, Moak SA, Ramamurthy NS, Golub LM. Tetracyclines supress MMP activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage. J Rheumatol 1992;19:927-938
33. Ciancio SG. Non-surgical periodontal treatment. In: Nevins M, Becker W, Kornman K, editors, Proceedings of the World Workshop in Clinical Periodontics. American Academy of Periodontology, Chicago; 1989. pp. II-4
34. Cannon CP, Curtis SP, Bolognese JA, Laine L. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J 2006;152:237-245 (Pubitemid 44109832)
35. Queiroz-Junior CM, Pacheco CMF, Maltos KLM, et al. Role of systemic and local administration of selective inhibitors of cyclooxygenase 1 and 2 in an experimental model of periodontal disease in rats. J Periodont Res 2009;44:153-160
36. Vardar S, Baylas H, Huseyinov A. Effects of selective cyclooxygenase-2 inhibition on gingival tissue levels of prostaglandin E2 and F2alpha and clinical parameters of chronic periodontitis. J Periodontol 2003;74:57-63